Skip to main content
BBNX logo

Beta Bionics, Inc.

BBNXNASDAQHealthcareMedical Devices

$16.39Today:- (-)1Y −13.54%

As of Oct 16, 2026 close

Market cap
$771.08M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$8.80$32.71
Volume (live)
-
Avg. volume (3M)
1.34M

Beta Bionics (BBNX) Cash Flow Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Beta Bionics used $50.92M of cash in operating activities and spent $5.30M on capital expenditures. That left free cash flow of −$56.22M.

Beta Bionics Cash Flow Statement Analysis

Values in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Beta Bionics, Inc. (BBNX) - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022
Period endingDec 2025Dec 2024Dec 2023Dec 2022
Operating Activities
Net Income-73.20-54.76-44.10-64.75
Depreciation & Amortization2.882.281.232.09
Stock Based Compensation16.386.385.666.10
Change in Working Capital-8.99-12.15-5.31-2.79
Change in Accounts Receivable-5.16-7.62-4.490.00
Change in Inventory-9.88-11.44-1.190.00
Change in Accounts Payable2.101.520.72-0.08
Change in Other Working Capital-2.055.39-2.51-2.71
Other Operating Activities-2.059.9610.08-0.85
Net Cash from Operating Activities-50.93-48.27-32.45-60.21
Investing Activities
Capital Expenditures-5.30-3.40-0.40-0.77
Purchases of Investments-327.51-72.13-69.300.00
Sales/Maturities of Investments170.0072.000.000.00
Other Investing Activities0.000.050.000.00
Net Cash from Investing Activities-162.81-3.48-69.69-0.77
Financing Activities
Common Stock Issued210.120.100.030.39
Other Financing Activities0.0055.51101.0056.39
Net Cash from Financing Activities214.8755.62101.0356.78
Summary
Net Change in Cash1.143.87-1.11-4.20
Cash at Beginning of Period30.5326.6727.7831.97
Cash at End of Period31.6830.5326.6727.78
Free Cash Flow-56.22-51.67-32.85-60.98

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Beta Bionics Cash Flow

What is Beta Bionics's free cash flow?

Beta Bionics had negative free cash flow of $56.22M in fiscal 2025 (fiscal year ended Dec 31, 2025), operating cash flow of −$50.92M minus $5.30M of capital expenditures.

How much does Beta Bionics spend on capital expenditures?

Beta Bionics spent $5.30M on capital expenditures in fiscal 2025, compared with $3.40M a year earlier.

Does Beta Bionics pay dividends or buy back shares?

Beta Bionics's cash flow statement for fiscal 2025 shows no dividend payments or share repurchases.

What is free cash flow?

Free cash flow is operating cash flow minus capital expenditures. It is the cash a company has left for dividends, buybacks, debt repayment or acquisitions after funding its operations and investment. Full definition